Learn · Models and translation
A useful model answers a bounded question. It does not stand in for a person.
Cells, model organisms, and selected human populations can reveal different parts of a problem. Translation asks whether the mechanism, exposure, outcome, duration, and safety still align in the next context.
What each model contributes
Choose the model for the question.
Similarity is not a verdict. The relevant question is which features the model preserves, which it leaves out, and whether those differences affect the claim.
Controlled mechanism
Isolates pathways and measurements, while omitting whole-body exposure, metabolism, behavior, disease history, and many safety interactions.
Fast lifespan experiments
Supports rapid genetic and lifespan work, but physiology, exposure, environment, and causes of death may differ sharply from people.
Integrated systems
Can resemble aspects of human organs and disease while retaining species, strain, husbandry, dose, and endpoint limits.
Closer biology, constrained evidence
Some systems are more comparable, yet studies can remain small, long, ethically constrained, and incomplete for human outcomes.
Directly human, not universally applicable
A trial in people answers only for its eligibility, setting, comparator, duration, adherence, outcomes, and uncertainty.
Translation under a new context
Different laboratories, populations, exposures, and endpoints can show where a result holds and where it changes.
The translation bridge
Seven points can break alignment.
- Model fitDoes the model reproduce the part of biology the claim depends on?
- Exposure and doseCan people reach a comparable exposure by a realistic route without unacceptable harm?
- TimingDid treatment begin before disease or aging changes that are already present in the intended population?
- DurationWas the study long enough for benefit, harm, adaptation, or loss of effect to appear?
- Outcome alignmentIs the measured endpoint the same outcome claimed, or only a biomarker or proxy?
- PopulationDo age, sex, genetics, health status, environment, medications, and baseline risk match?
- Safety and tradeoffsDo off-target effects, interactions, organ function, and competing risks change the result?
Do not make these jumps
A result stays inside its scope.
A pathway changed.
That supports a mechanistic claim, not improved function, healthspan, or lifespan.
A model improved.
That can justify further study, not a claim that people will experience the same effect.
A measurement moved.
The movement may be repeatable without proving how a person feels, functions, becomes ill, or lives.
A paper passed review.
Methods, reporting, conflicts, corrections, replication, and applicability still require examination.
A six-question translation check
Follow the claim across contexts.
- What feature made this model useful?
Name the bounded biological question rather than calling the model “good” or “bad.”
- What does the model omit?
List physiology, environment, disease, exposure, behavior, and time that are absent or simplified.
- Does the exposure translate?
Compare route, dose, concentration, frequency, timing, and duration.
- Does the endpoint translate?
Keep biomarkers, function, disease outcomes, healthspan, mortality, and lifespan separate.
- What human evidence exists?
Distinguish no evidence, indirect evidence, observational evidence, randomized evidence, and replication.
- What remains unknown?
State uncertainty explicitly; unknown does not mean false, safe, ineffective, or unavailable.